DOCETAXEL

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name
DOCETAXEL
Generic name
DOCETAXEL
Manufacturer
Accord Healthcare Inc.
Product type
HUMAN PRESCRIPTION DRUG
SPL set ID
f59f7811-70b7-4c44-99f7-4f4fdce3ed22
SPL ID
1fbda3cb-1ba1-490d-e063-6294a90a6777
Version
20
Effective date
2024-08-15
Source export date
2026-11-13
Source partition
1
Source file
https://download.open.fda.gov/drug/label/drug-label-0001-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/4245fd4310917b72c4a58c789d30a0b365e492ef46f48e107e3c3e16139b0499/drug-label-0001-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 15:27:58
Harmonized routes table
Harmonized routes
INTRAVENOUS

Boxed warning cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Boxed warning sections page 1 of 1 · 1 matching rows.

boxed warning

WARNING: TOXIC DEATHS, HEPATOTOXICITY, NEUTROPENIA, HYPERSENSITIVITY REACTIONS, and FLUID RETENTION Treatment-related mortality associated with Docetaxel Injection is increased in patients with abnormal liver function, in patients receiving higher doses, and in patients with non-small cell lung carcinoma and a history of prior treatment with platinum-based chemotherapy who receive Docetaxel Injection as a single agent at a dose of 100 mg/m 2 [see Warnings and Precautions (5.1) ]. Avoid the use of Docetaxel Injection in patients with bilirubin > upper limit of normal (ULN), or to patients with AST and/or ALT >1.5 × ULN concomitant with alkaline phosphatase >2.5 × ULN. Patients with elevations of bilirubin or abnormalities of transaminase concurrent with alkaline phosphatase are at increased risk for the development of severe neutropenia, febrile neutropenia, infections, severe thrombocytopenia, severe stomatitis, severe skin toxicity, and toxic death. Patients with isolated elevations of transaminase >1.5 × ULN also had a higher rate of febrile neutropenia. Measure bilirubin, AST or ALT, and alkaline phosphatase prior to each cycle of Docetaxel Injection [see Warnings and Precautions (5.2) ]. Do not administer Docetaxel Injection to patients with neutrophil counts of <1500 cells/mm 3 . Monitor blood counts frequently as neutropenia may be severe and result in infection [see Warnings and Precautions (5.3) ]. Do not administer Docetaxel Injection to patients who have a history of severe hypersensitivity reactions to Docetaxel Injection or to other drugs formulated with polysorbate 80 [see Contraindications (4) ] . Severe hypersensitivity reactions have been reported in patients despite dexamethasone premedication. Hypersensitivity reactions require immediate discontinuation of the Docetaxel Injection infusion and administration of appropriate therapy [see Warnings and Precautions (5.5) ] . Severe fluid retention occurred in 6.5% (6/92) of patients despite use of dexamethasone premedication. It was characterized by one or more of the following events: poorly tolerated peripheral edema, generalized edema, pleural effusion requiring urgent drainage, dyspnea at rest, cardiac tamponade, or pronounced abdominal distention (due to ascites) [see Warnings and Precautions (5.6) ]. WARNING: TOXIC DEATHS, HEPATOTOXICITY, NEUTROPENIA, HYPERSENSITIVITY REACTIONS, and FLUID RETENTION See full prescribing information for complete boxed warning. Treatment-related mortality increases with abnormal liver function, at higher doses, and in patients with NSCLC and prior platinum-based therapy receiving Docetaxel Injection at 100 mg/m 2 ( 5.1 ) Avoid use of Docetaxel Injection if bilirubin > ULN, or if AST and/or ALT >1.5 × ULN concomitant with alkaline phosphatase >2.5 × ULN. LFT elevations increase risk of severe or life-threatening complications. Obtain LFTs before each treatment cycle ( 5.2 ) Do not administer Docetaxel Injection to patients with neutrophil counts <1500 cells/mm 3 . Obtain frequent blood counts to monitor for neutropenia ( 4 , 5.3 ) Severe hypersensitivity, including fatal anaphylaxis, has been reported in patients who received dexamethasone premedication. Severe reactions require immediate discontinuation of Docetaxel Injection and administration of appropriate therapy ( 5.5 ) Contraindicated if history of severe hypersensitivity reactions to Docetaxel Injection or to drugs formulated with polysorbate 80 ( 4 ) Severe fluid retention may occur despite dexamethasone ( 5.6 )

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings and cautions

5 WARNINGS AND PRECAUTIONS Second primary malignancies: In patients treated with Docetaxel Injection-containing regimens, monitor for delayed AML, MDS, NHL, and renal cancer. ( 5.7 ) Cutaneous reactions: Reactions including erythema of the extremities with edema followed by desquamation may occur. Severe cutaneous adverse reactions have been reported. Severe skin toxicity may require dose adjustment or permanent treatment discontinuation. ( 5.8 ) Neurologic reactions: Reactions including paresthesia, dysesthesia, and pain may occur. Severe neurosensory symptoms require dose adjustment or discontinuation if persistent. ( 5.9 ) Eye disorders: Cystoid macular edema (CME) has been reported and requires treatment discontinuation. ( 5.10 ) Asthenia: Severe asthenia may occur and may require treatment discontinuation. ( 5.11 ) Embryo-fetal toxicity: Can cause fetal harm. Advise patients of the potential risk to a fetus and to use effective contraception. ( 5.12 , 8.1 , 8.3 ) Alcohol content: The alcohol content in a dose of Docetaxel Injection may affect the central nervous system. This may include impairment of a patient’s ability to drive or use machines immediately after infusion. ( 5.13 ) Tumor lysis syndrome: Tumor lysis syndrome has been reported. Patients at risk should be well hydrated and closely monitored during treatment. ( 5.14 ) 5.1 Toxic Deaths Breast Cancer Docetaxel administered at 100 mg/m 2 was associated with deaths considered possibly or probably related to treatment in 2.0% (19/965) of metastatic breast cancer patients, both previously treated and untreated, with normal baseline liver function and in 11.5% (7/61) of patients with various tumor types who had abnormal baseline liver function (AST and/or ALT >1.5 times ULN together with AP >2.5 times ULN). Among patients dosed at 60 mg/m 2 , mortality related to treatment occurred in 0.6% (3/481) of patients with normal liver function, and in 3 of 7 patients with abnormal liver function. Approximately half of these deaths occurred during the first cycle. Sepsis accounted for the majority of the deaths. Non-small Cell Lung Cancer Docetaxel administered at a dose of 100 mg/m 2 in patients with locally advanced or metastatic non-small cell lung cancer who had a history of prior platinum-based chemotherapy was associated with increased treatment-related mortality (14% and 5% in two randomized, controlled studies). There were 2.8% treatment-related deaths among the 176 patients treated at the 75 mg/m 2 dose in the randomized trials. Among patients who experienced treatment-related mortality at the 75 mg/m 2 dose level, 3 of 5 patients had an ECOG PS of 2 at study entry [see Dosage and Administration (2.2) , Clinical Studies (14) ]. 5.2 Hepatic Impairment Patients with elevations of bilirubin or abnormalities of transaminase concurrent with alkaline phosphatase are at increased risk for the development of severe neutropenia, febrile neutropenia, infections, severe thrombocytopenia, severe stomatitis, severe skin toxicity, and toxic death. Avoid Docetaxel Injection in patients with bilirubin > upper limit of normal (ULN), or to patients with AST and/or ALT >1.5 × ULN concomitant with alkaline phosphatase >2.5 × ULN [see Warnings and Precautions (5.1) ]. For patients with isolated elevations of transaminase >1.5 × ULN, consider Docetaxel Injection dose modifications [see Dosage and Administration (2.7) ]. Measure bilirubin, AST or ALT, and alkaline phosphatase prior to each cycle of Docetaxel Injection therapy. 5.3 Hematologic Effects Perform frequent peripheral blood cell counts on all patients receiving Docetaxel Injection. Do not retreat patients with subsequent cycles of Docetaxel Injection until neutrophils recover to a level >1500 cells/mm 3 [see Contraindications (4) ]. Avoid retreating patients until platelets recover to a level >100,000 cells/mm 3 . A 25% reduction in the dose of Docetaxel Injection is recommended during subsequent cycles following severe neutropenia (<500 cells/mm 3 ) lasting 7 days or more, febrile neutropenia, or a grade 4 infection in a Docetaxel Injection cycle [see Dosage and Administration (2.7) ]. Neutropenia (<2000 neutrophils/mm 3 ) occurs in virtually all patients given 60 mg/m 2 to 100 mg/m 2 of Docetaxel Injection and grade 4 neutropenia (<500 cells/mm 3 ) occurs in 85% of patients given 100 mg/m 2 and 75% of patients given 60 mg/m 2 . Frequent monitoring of blood counts is, therefore, essential so that dose can be adjusted. Docetaxel Injection should not be administered to patients with neutrophils <1500 cells/mm 3 . Febrile neutropenia occurred in about 12% of patients given 100 mg/m 2 but was very uncommon in patients given 60 mg/m 2 . Hematologic responses, febrile reactions and infections, and rates of septic death for different regimens are dose related [see Adverse Reactions (6.1), Clinical Studies (14) ]. Three breast cancer patients with severe liver impairment (bilirubin >1.7 times ULN) developed fatal gastrointestinal bleeding associated with severe drug-induced thrombocytopenia. In gastric cancer patients treated with docetaxel in combination with cisplatin and fluorouracil (TCF), febrile neutropenia and/or neutropenic infection occurred in 12% of patients receiving G-CSF compared to 28% who did not. Patients receiving TCF should be closely monitored during the first and subsequent cycles for febrile neutropenia and neutropenic infection [see Dosage and Administration (2.7) , Adverse Reactions (6) ] 5.4 Enterocolitis and Neutropenic Colitis Enterocolitis and neutropenic colitis (typhlitis) have occurred in patients treated with Docetaxel Injection alone and in combination with other chemotherapeutic agents, despite the coadministration of G-CSF. Caution is recommended for patients with neutropenia, particularly at risk for developing gastrointestinal complications. Enterocolitis and neutropenic enterocolitis may develop at any time, and could lead to death as early as the first day of symptom onset. Monitor patients closely from onset of any symptoms of gastrointestinal toxicity. Inform patients to contact their healthcare provider with new, or worsening symptoms of gastrointestinal toxicity [see Dosage and Administration (2) , Warnings and Precautions (5.3) , Adverse Reactions (6.2) ]. 5.5 Hypersensitivity Reactions Monitor patients closely for hypersensitivity reactions, especially during the first and second infusions. Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients pre-medicated with 3 days of corticosteroids. Severe hypersensitivity reactions require immediate discontinuation of the Docetaxel Injection infusion and aggressive therapy. Do not rechallenge patients with a history of severe hypersensitivity reactions with Docetaxel Injection [see Contraindications (4) ]. Patients who have previously experienced a hypersensitivity reaction to paclitaxel may develop a hypersensitivity reaction to docetaxel that may include severe or fatal reactions such as anaphylaxis. Monitor patients with a previous history of hypersensitivity to paclitaxel closely during initiation of docetaxel therapy. Hypersensitivity reactions may occur within a few minutes following initiation of a Docetaxel Injection infusion. If minor reactions such as flushing or localized skin reactions occur, interruption of therapy is not required. All patients should be premedicated with an oral corticosteroid prior to the initiation of the infusion of Docetaxel Injection [see Dosage and Administration (2.6) ] . 5.6 Fluid Retention Severe fluid retention has been reported following docetaxel therapy. Patients should be premedicated with oral corticosteroids prior to each Docetaxel Injection administration to reduce the incidence and severity of fluid retention [see Dosage and Administration (2.6) ]. Patients with pre-existing effusions should be closely monitored from the first dose for the possible exacerbation of the effusions. When fluid retention occurs, peripheral edema usually starts in the lower extremities and may become generalized with a median weight gain of 2 kg. Among 92 breast cancer patients premedicated with 3-day corticosteroids, moderate fluid retention occurred in 27.2% and severe fluid retention in 6.5%. The median cumulative dose to onset of moderate or severe fluid retention was 819 mg/m 2 . Nine of 92 patients (9.8%) of patients discontinued treatment due to fluid retention: 4 patients discontinued with severe fluid retention; the remaining 5 had mild or moderate fluid retention. The median cumulative dose to treatment discontinuation due to fluid retention was 1021 mg/m 2 . Fluid retention was completely, but sometimes slowly, reversible with a median of 16 weeks from the last infusion of docetaxel to resolution (range: 0 to 42+ weeks). Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). 5.7 Second Primary Malignancies Second primary malignancies, notably acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), non-Hodgkin’s lymphoma (NHL), and renal cancer, have been reported in patients treated with docetaxel-containing regimens. These adverse reactions may occur several months or years after docetaxel-containing therapy. Treatment-related AML or MDS has occurred in patients given anthracyclines and/or cyclophosphamide, including use in adjuvant therapy for breast cancer. In the adjuvant breast cancer trial (TAX316) AML occurred in 3 of 744 patients who received docetaxel, doxorubicin and cyclophosphamide (TAC) and in 1 of 736 patients who received fluorouracil, doxorubicin, and cyclophosphamide In TAC-treated patients, the risk of delayed myelodysplasia or myeloid leukemia requires hematological follow-up. Monitor patients for second primary malignancies Treatment-related AML or MDS has occurred in patients given anthracyclines and/or cyclophosphamide, including use in adjuvant therapy for breast cancer. In the adjuvant breast cancer trial (TAX316) AML occurred in 3 of 744 patients who received docetaxel, doxorubicin and cyclophosphamide (TAC) and in 1 of 736 patients who received fluorouracil, doxorubicin, and cyclophosphamide [see Clinical Studies (14.2) ]. In TAC-treated patients, the risk of delayed myelodysplasia or myeloid leukemia requires hematological follow-up. Monitor patients for second primary malignancies [see Adverse Reactions (6.1) ]. 5.8 Cutaneous Reactions Localized erythema of the extremities with edema followed by desquamation has been observed. In case of severe skin toxicity, an adjustment in dosage is recommended The discontinuation rate due to skin toxicity was 1.6% (15/965) for metastatic breast cancer patients. Among 92 breast cancer patients premedicated with 3-day corticosteroids, there were no cases of severe skin toxicity reported and no patient discontinued docetaxel due to skin toxicity. Localized erythema of the extremities with edema followed by desquamation has been observed. In case of severe skin toxicity, an adjustment in dosage is recommended [see Dosage and Administration (2.7) ]. The discontinuation rate due to skin toxicity was 1.6% (15/965) for metastatic breast cancer patients. Among 92 breast cancer patients premedicated with 3-day corticosteroids, there were no cases of severe skin toxicity reported and no patient discontinued docetaxel due to skin toxicity. Severe cutaneous adverse reactions (SCARs) such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and acute generalized exanthematous pustulosis (AGEP) have been reported in association with docetaxel treatment. Patients should be informed about the signs and symptoms of serious skin manifestations and monitored closely. Permanent treatment discontinuation should be considered in patients who experience SCARs. 5.9 Neurologic Reactions Severe neurosensory symptoms (e.g. paresthesia, dysesthesia, pain) were observed in 5.5% (53/965) of metastatic breast cancer patients, and resulted in treatment discontinuation in 6.1%. When these symptoms occur, dosage must be adjusted. If symptoms persist, treatment should be discontinued [see Dosage and Administration (2.7) ]. Patients who experienced neurotoxicity in clinical trials and for whom follow-up information on the complete resolution of the event was available had spontaneous reversal of symptoms with a median of 9 weeks from onset (range: 0 to 106 weeks). Severe peripheral motor neuropathy mainly manifested as distal extremity weakness occurred in 4.4% (42/965). 5.10 Eye Disorders Cystoid macular edema (CME) has been reported in patients treated with Docetaxel Injection. Patients with impaired vision should undergo a prompt and comprehensive ophthalmologic examination. If CME is diagnosed, Docetaxel Injection treatment should be discontinued and appropriate treatment initiated. Alternative non-taxane cancer treatment should be considered. 5.11 Asthenia Severe asthenia has been reported in 14.9% (144/965) of metastatic breast cancer patients but has led to treatment discontinuation in only 1.8%. Symptoms of fatigue and weakness may last a few days up to several weeks and may be associated with deterioration of performance status in patients with progressive disease. 5.12 Embryo-Fetal Toxicity Based on findings from animal reproduction studies and its mechanism of action, docetaxel can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1) ]. Available data from case reports in the literature and pharmacovigilance with docetaxel use in pregnant women are not sufficient to inform the drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. In animal reproduction studies, administration of docetaxel to pregnant rats and rabbits during the period of organogenesis caused embryo-fetal toxicities, including intrauterine mortality, at doses as low as 0.02 and 0.003 times the recommended human dose based on body surface area, respectively. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Verify pregnancy status in females of reproductive potential prior to initiating docetaxel. Advise females of reproductive potential to use effective contraception during treatment and for 2 months after the last dose of docetaxel. Advise male patients with female partners of reproductive potential to use effective contraception during treatment and for 4 months after the last dose of docetaxel [see Use in Specific Populations (8.1 , 8.3) ]. 5.13 Alcohol Content Cases of intoxication have been reported with some formulations of docetaxel due to the alcohol content. The alcohol content in a dose of Docetaxel Injection may affect the central nervous system and should be taken into account for patients in whom alcohol intake should be avoided or minimized. Consideration should be given to the alcohol content in Docetaxel Injection on the ability to drive or use machines immediately after the infusion. Each administration of Docetaxel Injection at 100 mg/m 2 delivers 1.975 g/m 2 of ethanol. For a patient with a BSA of 2.0 m 2 , this would deliver 3.95 grams of ethanol [see Description (11) ] . Other docetaxel products may have a different amount of alcohol. 5.14 Tumor Lysis Syndrome Tumor lysis syndrome has been reported with docetaxel [see Adverse Reactions (6.2) ] . Patients at risk of tumor lysis syndrome (e.g., with renal impairment, hyperuricemia, bulky tumor) should be closely monitored prior to initiating Docetaxel Injection and periodically during treatment. Correction of dehydration and treatment of high uric acid levels are recommended prior to initiation of treatment.

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 2 of 3 · 10 matching rows.

adverse reactions table

<table ID="table6" width="100%"><caption>Table 6: Clinically Important Treatment-Emergent Adverse Reactions Regardless of Causal Relationship in Patients Receiving Docetaxel in Combination with Doxorubicin and Cyclophosphamide (TAX316).</caption><col align="left" valign="middle" width="40%"/><col align="center" valign="middle" width="15%"/><col align="center" valign="middle" width="15%"/><col align="center" valign="middle" width="15%"/><col align="center" valign="middle" width="15%"/><thead><tr styleCode="Botrule"><th styleCode="Lrule Rrule"/><th colspan="2" styleCode="Rrule" valign="top">Docetaxel 75 mg/m <sup>2</sup>+ Doxorubicin 50 mg/m <sup>2</sup>+ Cyclophosphamide 500 mg/m <sup>2</sup>(TAC) n=744 % </th><th colspan="2" styleCode="Rrule" valign="top">Fluorouracil 500 mg/m <sup>2</sup>+ Doxorubicin 50 mg/m <sup>2</sup>+ Cyclophosphamide 500 mg/m <sup>2</sup>(FAC) n=736 % </th></tr><tr><th styleCode="Lrule Rrule">Adverse Reaction</th><th styleCode="Rrule">Any</th><th styleCode="Rrule">Grade 3/4</th><th styleCode="Rrule">Any</th><th styleCode="Rrule">Grade 3/4</th></tr></thead><tbody><tr styleCode="Botrule"><td styleCode="Lrule Rrule"><content styleCode="bold">Anemia</content></td><td styleCode="Rrule">92</td><td styleCode="Rrule">4</td><td styleCode="Rrule">72</td><td styleCode="Rrule">2</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule"><content styleCode="bold">Neutropenia</content></td><td styleCode="Rrule">71</td><td styleCode="Rrule">66</td><td styleCode="Rrule">82</td><td styleCode="Rrule">49</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule"><content styleCode="bold">Fever in absence of infection</content></td><td styleCode="Rrule">47</td><td styleCode="Rrule">1</td><td styleCode="Rrule">17</td><td styleCode="Rrule">0</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule"><content styleCode="bold">Infection</content></td><td styleCode="Rrule">39</td><td styleCode="Rrule">4</td><td styleCode="Rrule">36</td><td styleCode="Rrule">2</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule"><content styleCode="bold">Thrombocytopenia</content></td><td styleCode="Rrule">39</td><td styleCode="Rrule">2</td><td styleCode="Rrule">28</td><td styleCode="Rrule">1</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule"><content styleCode="bold">Febrile neutropenia</content></td><td styleCode="Rrule">25</td><td styleCode="Rrule">N/A</td><td styleCode="Rrule">3</td><td styleCode="Rrule">N/A</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule"><content styleCode="bold">Neutropenic infection</content></td><td styleCode="Rrule">12</td><td styleCode="Rrule">N/A</td><td styleCode="Rrule">6</td><td styleCode="Rrule">N/A</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule"><content styleCode="bold">Hypersensitivity reactions</content></td><td styleCode="Rrule">13</td><td styleCode="Rrule">1</td><td styleCode="Rrule">4</td><td styleCode="Rrule">0</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule"><content styleCode="bold">Lymphedema</content></td><td styleCode="Rrule">4</td><td styleCode="Rrule">0</td><td styleCode="Rrule">1</td><td styleCode="Rrule">0</td></tr><tr><td styleCode="Lrule Rrule"><content styleCode="bold">Fluid Retention <footnote ID="t7ft">COSTART term and grading system for events related to treatment.</footnote></content></td><td styleCode="Rrule">35</td><td styleCode="Rrule">1</td><td styleCode="Rrule">15</td><td styleCode="Rrule">0</td></tr><tr><td styleCode="Lrule Rrule">Peripheral edema</td><td styleCode="Rrule">27</td><td styleCode="Rrule">0</td><td styleCode="Rrule">7</td><td styleCode="Rrule">0</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Weight gain</td><td styleCode="Rrule">13</td><td styleCode="Rrule">0</td><td styleCode="Rrule">9</td><td styleCode="Rrule">0</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule"><content styleCode="bold">Neuropathy sensory</content></td><td styleCode="Rrule">26</td><td styleCode="Rrule">0</td><td styleCode="Rrule">10</td><td styleCode="Rrule">0</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule"><content styleCode="bold">Neuro-cortical</content></td><td styleCode="Rrule">5</td><td styleCode="Rrule">1</td><td styleCode="Rrule">6</td><td styleCode="Rrule">1</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule"><content styleCode="bold">Neuropathy motor</content></td><td styleCode="Rrule">4</td><td styleCode="Rrule">0</td><td styleCode="Rrule">2</td><td styleCode="Rrule">0</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule"><content styleCode="bold">Neuro-cerebellar</content></td><td styleCode="Rrule">2</td><td styleCode="Rrule">0</td><td styleCode="Rrule">2</td><td styleCode="Rrule">0</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule"><content styleCode="bold">Syncope</content></td><td styleCode="Rrule">2</td><td styleCode="Rrule">1</td><td styleCode="Rrule">1</td><td styleCode="Rrule">0</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule"><content styleCode="bold">Alopecia</content></td><td styleCode="Rrule">98</td><td styleCode="Rrule">N/A</td><td styleCode="Rrule">97</td><td styleCode="Rrule">N/A</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule"><content styleCode="bold">Skin toxicity</content></td><td styleCode="Rrule">27</td><td styleCode="Rrule">1</td><td styleCode="Rrule">18</td><td styleCode="Rrule">0</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule"><content styleCode="bold">Nail disorders</content></td><td styleCode="Rrule">19</td><td styleCode="Rrule">0</td><td styleCode="Rrule">14</td><td styleCode="Rrule">0</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule"><content styleCode="bold">Nausea</content></td><td styleCode="Rrule">81</td><td styleCode="Rrule">5</td><td styleCode="Rrule">88</td><td styleCode="Rrule">10</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule"><content styleCode="bold">Stomatitis</content></td><td styleCode="Rrule">69</td><td styleCode="Rrule">7</td><td styleCode="Rrule">53</td><td styleCode="Rrule">2</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule"><content styleCode="bold">Vomiting</content></td><td styleCode="Rrule">45</td><td styleCode="Rrule">4</td><td styleCode="Rrule">59</td><td styleCode="Rrule">7</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule"><content styleCode="bold">Diarrhea</content></td><td styleCode="Rrule">35</td><td styleCode="Rrule">4</td><td styleCode="Rrule">28</td><td styleCode="Rrule">2</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule"><content styleCode="bold">Constipation</content></td><td styleCode="Rrule">34</td><td styleCode="Rrule">1</td><td styleCode="Rrule">32</td><td styleCode="Rrule">1</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule"><content styleCode="bold">Taste perversion</content></td><td styleCode="Rrule">28</td><td styleCode="Rrule">1</td><td styleCode="Rrule">15</td><td styleCode="Rrule">0</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule"><content styleCode="bold">Anorexia</content></td><td styleCode="Rrule">22</td><td styleCode="Rrule">2</td><td styleCode="Rrule">18</td><td styleCode="Rrule">1</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule"><content styleCode="bold">Abdominal Pain</content></td><td styleCode="Rrule">11</td><td styleCode="Rrule">1</td><td styleCode="Rrule">5</td><td styleCode="Rrule">0</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule"><content styleCode="bold">Amenorrhea</content></td><td styleCode="Rrule">62</td><td styleCode="Rrule">N/A</td><td styleCode="Rrule">52</td><td styleCode="Rrule">N/A</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule"><content styleCode="bold">Cough</content></td><td styleCode="Rrule">14</td><td styleCode="Rrule">0</td><td styleCode="Rrule">10</td><td styleCode="Rrule">0</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule"><content styleCode="bold">Cardiac dysrhythmias</content></td><td styleCode="Rrule">8</td><td styleCode="Rrule">0</td><td styleCode="Rrule">6</td><td styleCode="Rrule">0</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule"><content styleCode="bold">Vasodilatation</content></td><td styleCode="Rrule">27</td><td styleCode="Rrule">1</td><td styleCode="Rrule">21</td><td styleCode="Rrule">1</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule"><content styleCode="bold">Hypotension</content></td><td styleCode="Rrule">2</td><td styleCode="Rrule">0</td><td styleCode="Rrule">1</td><td styleCode="Rrule">0</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule"><content styleCode="bold">Phlebitis</content></td><td styleCode="Rrule">1</td><td styleCode="Rrule">0</td><td styleCode="Rrule">1</td><td styleCode="Rrule">0</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule"><content styleCode="bold">Asthenia</content></td><td styleCode="Rrule">81</td><td styleCode="Rrule">11</td><td styleCode="Rrule">71</td><td styleCode="Rrule">6</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule"><content styleCode="bold">Myalgia</content></td><td styleCode="Rrule">27</td><td styleCode="Rrule">1</td><td styleCode="Rrule">10</td><td styleCode="Rrule">0</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule"><content styleCode="bold">Arthralgia</content></td><td styleCode="Rrule">19</td><td styleCode="Rrule">1</td><td styleCode="Rrule">9</td><td styleCode="Rrule">0</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule"><content styleCode="bold">Lacrimation disorder</content></td><td styleCode="Rrule">11</td><td styleCode="Rrule">0</td><td styleCode="Rrule">7</td><td styleCode="Rrule">0</td></tr><tr><td styleCode="Lrule Rrule"><content styleCode="bold">Conjunctivitis</content></td><td styleCode="Rrule">5</td><td styleCode="Rrule">0</td><td styleCode="Rrule">7</td><td styleCode="Rrule">0</td></tr></tbody></table>

adverse reactions table

<table ID="table7" width="100%"><caption>Table 7: Treatment-Emergent Adverse Reactions Regardless of Relationship to Treatment in Patients Receiving Docetaxel as Monotherapy for Non-small Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy <footnote ID="K5621">Normal Baseline LFTs: Transaminases &#x2264;1.5 times ULN or alkaline phosphatase &#x2264;2.5 times ULN or isolated elevations of transaminases or alkaline phosphatase up to 5 times ULN</footnote></caption><col align="left" valign="top" width="34%"/><col align="center" valign="top" width="22%"/><col align="center" valign="top" width="22%"/><col align="center" valign="top" width="22%"/><thead><tr><th styleCode="Lrule" valign="bottom">Adverse Reaction</th><th styleCode="Lrule" valign="bottom">Docetaxel 75 mg/m <sup>2</sup> n=176 % </th><th styleCode="Lrule" valign="bottom">Best Supportive Care n=49 % </th><th styleCode="Lrule Rrule" valign="bottom">Vinorelbine/Ifosfamide n=119 % </th></tr></thead><tbody><tr><td styleCode="Lrule"><content styleCode="bold">Neutropenia</content></td><td styleCode="Lrule"/><td styleCode="Lrule"/><td styleCode="Lrule Rrule"/></tr><tr><td styleCode="Lrule"> Any</td><td styleCode="Lrule">84</td><td styleCode="Lrule">14</td><td styleCode="Lrule Rrule">83</td></tr><tr styleCode="Botrule"><td styleCode="Lrule"> Grade 3/4</td><td styleCode="Lrule">65</td><td styleCode="Lrule">12</td><td styleCode="Lrule Rrule">57</td></tr><tr><td styleCode="Lrule"><content styleCode="bold">Leukopenia</content></td><td styleCode="Lrule"/><td styleCode="Lrule"/><td styleCode="Lrule Rrule"/></tr><tr><td styleCode="Lrule"> Any</td><td styleCode="Lrule">84</td><td styleCode="Lrule">6</td><td styleCode="Lrule Rrule">89</td></tr><tr styleCode="Botrule"><td styleCode="Lrule"> Grade 3/4</td><td styleCode="Lrule">49</td><td styleCode="Lrule">0</td><td styleCode="Lrule Rrule">43</td></tr><tr><td styleCode="Lrule"><content styleCode="bold">Thrombocytopenia</content></td><td styleCode="Lrule"/><td styleCode="Lrule"/><td styleCode="Lrule Rrule"/></tr><tr><td styleCode="Lrule"> Any</td><td styleCode="Lrule">8</td><td styleCode="Lrule">0</td><td styleCode="Lrule Rrule">8</td></tr><tr styleCode="Botrule"><td styleCode="Lrule"> Grade 3/4</td><td styleCode="Lrule">3</td><td styleCode="Lrule">0</td><td styleCode="Lrule Rrule">2</td></tr><tr><td styleCode="Lrule"><content styleCode="bold">Anemia</content></td><td styleCode="Lrule"/><td styleCode="Lrule"/><td styleCode="Lrule Rrule"/></tr><tr><td styleCode="Lrule"> Any</td><td styleCode="Lrule">91</td><td styleCode="Lrule">55</td><td styleCode="Lrule Rrule">91</td></tr><tr styleCode="Botrule"><td styleCode="Lrule"> Grade 3/4</td><td styleCode="Lrule">9</td><td styleCode="Lrule">12</td><td styleCode="Lrule Rrule">14</td></tr><tr styleCode="Botrule"><td styleCode="Lrule"><content styleCode="bold">Febrile Neutropenia</content><footnote ID="K5837">Febrile Neutropenia: ANC grade 4 with fever &gt;38&#xB0;C with intravenous antibiotics and/or hospitalization</footnote></td><td styleCode="Lrule">6</td><td styleCode="Lrule">NA <footnote ID="Footnote3">Not Applicable;</footnote></td><td styleCode="Lrule Rrule">1</td></tr><tr><td styleCode="Lrule"><content styleCode="bold">Infection</content></td><td styleCode="Lrule"/><td styleCode="Lrule"/><td styleCode="Lrule Rrule"/></tr><tr><td styleCode="Lrule"> Any</td><td styleCode="Lrule">34</td><td styleCode="Lrule">29</td><td styleCode="Lrule Rrule">30</td></tr><tr styleCode="Botrule"><td styleCode="Lrule"> Grade 3/4</td><td styleCode="Lrule">10</td><td styleCode="Lrule">6</td><td styleCode="Lrule Rrule">9</td></tr><tr styleCode="Botrule"><td styleCode="Lrule"><content styleCode="bold">Treatment Related Mortality</content></td><td styleCode="Lrule" valign="bottom">3</td><td styleCode="Lrule" valign="bottom">NA <footnoteRef IDREF="Footnote3"/></td><td styleCode="Lrule Rrule" valign="bottom">3</td></tr><tr><td styleCode="Lrule"><content styleCode="bold">Hypersensitivity Reactions</content></td><td styleCode="Lrule"/><td styleCode="Lrule"/><td styleCode="Lrule Rrule"/></tr><tr><td styleCode="Lrule"> Any</td><td styleCode="Lrule">6</td><td styleCode="Lrule">0</td><td styleCode="Lrule Rrule">1</td></tr><tr styleCode="Botrule"><td styleCode="Lrule"> Grade 3/4</td><td styleCode="Lrule">3</td><td styleCode="Lrule">0</td><td styleCode="Lrule Rrule">0</td></tr><tr><td styleCode="Lrule"><content styleCode="bold">Fluid Retention</content></td><td styleCode="Lrule"/><td styleCode="Lrule"/><td styleCode="Lrule Rrule"/></tr><tr><td styleCode="Lrule"> Any</td><td styleCode="Lrule">34</td><td styleCode="Lrule">ND <footnote ID="K5972">Not Done</footnote></td><td styleCode="Lrule Rrule">23</td></tr><tr styleCode="Botrule"><td styleCode="Lrule"> Severe</td><td styleCode="Lrule">3</td><td styleCode="Lrule"/><td styleCode="Lrule Rrule">3</td></tr><tr><td styleCode="Lrule"><content styleCode="bold">Neurosensory</content></td><td styleCode="Lrule"/><td styleCode="Lrule"/><td styleCode="Lrule Rrule"/></tr><tr><td styleCode="Lrule"> Any</td><td styleCode="Lrule">23</td><td styleCode="Lrule">14</td><td styleCode="Lrule Rrule">29</td></tr><tr styleCode="Botrule"><td styleCode="Lrule"> Grade 3/4</td><td styleCode="Lrule">2</td><td styleCode="Lrule">6</td><td styleCode="Lrule Rrule">5</td></tr><tr><td styleCode="Lrule"><content styleCode="bold">Neuromotor</content></td><td styleCode="Lrule"/><td styleCode="Lrule"/><td styleCode="Lrule Rrule"/></tr><tr><td styleCode="Lrule"> Any</td><td styleCode="Lrule">16</td><td styleCode="Lrule">8</td><td styleCode="Lrule Rrule">10</td></tr><tr styleCode="Botrule"><td styleCode="Lrule"> Grade 3/4</td><td styleCode="Lrule">5</td><td styleCode="Lrule">6</td><td styleCode="Lrule Rrule">3</td></tr><tr><td styleCode="Lrule"><content styleCode="bold">Skin</content></td><td styleCode="Lrule"/><td styleCode="Lrule"/><td styleCode="Lrule Rrule"/></tr><tr><td styleCode="Lrule"> Any</td><td styleCode="Lrule">20</td><td styleCode="Lrule">6</td><td styleCode="Lrule Rrule">17</td></tr><tr styleCode="Botrule"><td styleCode="Lrule"> Grade 3/4</td><td styleCode="Lrule">1</td><td styleCode="Lrule">2</td><td styleCode="Lrule Rrule">1</td></tr><tr><td styleCode="Lrule"><content styleCode="bold">Gastrointestinal</content></td><td styleCode="Lrule"/><td styleCode="Lrule"/><td styleCode="Lrule Rrule"/></tr><tr><td styleCode="Lrule"> Nausea</td><td styleCode="Lrule"/><td styleCode="Lrule"/><td styleCode="Lrule Rrule"/></tr><tr><td styleCode="Lrule"> Any</td><td styleCode="Lrule">34</td><td styleCode="Lrule">31</td><td styleCode="Lrule Rrule">31</td></tr><tr><td styleCode="Lrule"> Grade 3/4</td><td styleCode="Lrule">5</td><td styleCode="Lrule">4</td><td styleCode="Lrule Rrule">8</td></tr><tr><td styleCode="Lrule"> Vomiting</td><td styleCode="Lrule"/><td styleCode="Lrule"/><td styleCode="Lrule Rrule"/></tr><tr><td styleCode="Lrule"> Any</td><td styleCode="Lrule">22</td><td styleCode="Lrule">27</td><td styleCode="Lrule Rrule">22</td></tr><tr><td styleCode="Lrule"> Grade 3/4</td><td styleCode="Lrule">3</td><td styleCode="Lrule">2</td><td styleCode="Lrule Rrule">6</td></tr><tr><td styleCode="Lrule"> Diarrhea</td><td styleCode="Lrule"/><td styleCode="Lrule"/><td styleCode="Lrule Rrule"/></tr><tr><td styleCode="Lrule"> Any</td><td styleCode="Lrule">23</td><td styleCode="Lrule">6</td><td styleCode="Lrule Rrule">12</td></tr><tr styleCode="Botrule"><td styleCode="Lrule">Grade 3/4</td><td styleCode="Lrule">3</td><td styleCode="Lrule">0</td><td styleCode="Lrule Rrule">4</td></tr><tr styleCode="Botrule"><td styleCode="Lrule"><content styleCode="bold">Alopecia</content></td><td styleCode="Lrule">56</td><td styleCode="Lrule">35</td><td styleCode="Lrule Rrule">50</td></tr><tr><td styleCode="Lrule"><content styleCode="bold">Asthenia</content></td><td styleCode="Lrule"/><td styleCode="Lrule"/><td styleCode="Lrule Rrule"/></tr><tr><td styleCode="Lrule"> Any</td><td styleCode="Lrule">53</td><td styleCode="Lrule">57</td><td styleCode="Lrule Rrule">54</td></tr><tr styleCode="Botrule"><td styleCode="Lrule"> Severe <footnote ID="Footnote4">COSTART term and grading system</footnote></td><td styleCode="Lrule">18</td><td styleCode="Lrule">39</td><td styleCode="Lrule Rrule">23</td></tr><tr><td styleCode="Lrule"><content styleCode="bold">Stomatitis</content></td><td styleCode="Lrule"/><td styleCode="Lrule"/><td styleCode="Lrule Rrule"/></tr><tr><td styleCode="Lrule"> Any</td><td styleCode="Lrule">26</td><td styleCode="Lrule">6</td><td styleCode="Lrule Rrule">8</td></tr><tr styleCode="Botrule"><td styleCode="Lrule"> Grade 3/4</td><td styleCode="Lrule">2</td><td styleCode="Lrule">0</td><td styleCode="Lrule Rrule">1</td></tr><tr><td styleCode="Lrule"><content styleCode="bold">Pulmonary</content></td><td styleCode="Lrule"/><td styleCode="Lrule"/><td styleCode="Lrule Rrule"/></tr><tr><td styleCode="Lrule"> Any</td><td styleCode="Lrule">41</td><td styleCode="Lrule">49</td><td styleCode="Lrule Rrule">45</td></tr><tr styleCode="Botrule"><td styleCode="Lrule"> Grade 3/4</td><td styleCode="Lrule">21</td><td styleCode="Lrule">29</td><td styleCode="Lrule Rrule">19</td></tr><tr><td styleCode="Lrule"><content styleCode="bold">Nail Disorder</content></td><td styleCode="Lrule"/><td styleCode="Lrule"/><td styleCode="Lrule Rrule"/></tr><tr><td styleCode="Lrule"> Any</td><td styleCode="Lrule">11</td><td styleCode="Lrule">0</td><td styleCode="Lrule Rrule">2</td></tr><tr styleCode="Botrule"><td styleCode="Lrule"> Severe <footnoteRef IDREF="Footnote4"/></td><td styleCode="Lrule">1</td><td styleCode="Lrule">0</td><td styleCode="Lrule Rrule">0</td></tr><tr><td styleCode="Lrule"><content styleCode="bold">Myalgia</content></td><td styleCode="Lrule"/><td styleCode="Lrule"/><td styleCode="Lrule Rrule"/></tr><tr><td styleCode="Lrule"> Any</td><td styleCode="Lrule">6</td><td styleCode="Lrule">0</td><td styleCode="Lrule Rrule">3</td></tr><tr styleCode="Botrule"><td styleCode="Lrule"> Severe <footnoteRef IDREF="Footnote4"/></td><td styleCode="Lrule">0</td><td styleCode="Lrule">0</td><td styleCode="Lrule Rrule">0</td></tr><tr><td styleCode="Lrule"><content styleCode="bold">Arthralgia</content></td><td styleCode="Lrule"/><td styleCode="Lrule"/><td styleCode="Lrule Rrule"/></tr><tr><td styleCode="Lrule"> Any</td><td styleCode="Lrule">3</td><td styleCode="Lrule">2</td><td styleCode="Lrule Rrule">2</td></tr><tr styleCode="Botrule"><td styleCode="Lrule"> Severe <footnoteRef IDREF="Footnote4"/></td><td styleCode="Lrule">0</td><td styleCode="Lrule">0</td><td styleCode="Lrule Rrule">1</td></tr><tr><td styleCode="Lrule"><content styleCode="bold">Taste Perversion</content></td><td styleCode="Lrule"/><td styleCode="Lrule"/><td styleCode="Lrule Rrule"/></tr><tr><td styleCode="Lrule"> Any</td><td styleCode="Lrule">6</td><td styleCode="Lrule">0</td><td styleCode="Lrule Rrule">0</td></tr><tr><td styleCode="Lrule"> Severe <footnoteRef IDREF="Footnote4"/></td><td styleCode="Lrule">1</td><td styleCode="Lrule">0</td><td styleCode="Lrule Rrule">0</td></tr></tbody></table>

adverse reactions table

<table ID="table8" width="75%"><caption>Table 8: Adverse Reactions Regardless of Relationship to Treatment in Chemotherapy- Naive Advanced Non-small Cell Lung Cancer Patients Receiving Docetaxel in Combination with Cisplatin</caption><col align="left" valign="top" width="50%"/><col align="center" valign="top" width="25%"/><col align="center" valign="top" width="25%"/><thead><tr><th styleCode="Lrule" valign="bottom">Adverse Reaction </th><th styleCode="Lrule" valign="bottom">Docetaxel 75 mg/m <sup>2</sup>+ Cisplatin 75 mg/m <sup>2</sup> n=406 % </th><th styleCode="Lrule Rrule" valign="top">Vinorelbine 25 mg/m <sup>2</sup>+ Cisplatin 100 mg/m <sup>2</sup> n=396 % </th></tr></thead><tbody><tr><td styleCode="Lrule"><content styleCode="bold">Neutropenia</content></td><td styleCode="Lrule"/><td styleCode="Lrule Rrule"/></tr><tr><td styleCode="Lrule"> Any</td><td styleCode="Lrule">91</td><td styleCode="Lrule Rrule">90</td></tr><tr styleCode="Botrule"><td styleCode="Lrule"> Grade 3/4</td><td styleCode="Lrule">74</td><td styleCode="Lrule Rrule">78</td></tr><tr styleCode="Botrule"><td styleCode="Lrule"><content styleCode="bold">Febrile Neutropenia</content></td><td styleCode="Lrule">5</td><td styleCode="Lrule Rrule">5</td></tr><tr><td styleCode="Lrule"><content styleCode="bold">Thrombocytopenia</content></td><td styleCode="Lrule"/><td styleCode="Lrule Rrule"/></tr><tr><td styleCode="Lrule"> Any</td><td styleCode="Lrule">15</td><td styleCode="Lrule Rrule">15</td></tr><tr styleCode="Botrule"><td styleCode="Lrule"> Grade 3/4</td><td styleCode="Lrule">3</td><td styleCode="Lrule Rrule">4</td></tr><tr><td styleCode="Lrule"><content styleCode="bold">Anemia</content></td><td styleCode="Lrule"/><td styleCode="Lrule Rrule"/></tr><tr><td styleCode="Lrule"> Any</td><td styleCode="Lrule">89</td><td styleCode="Lrule Rrule">94</td></tr><tr styleCode="Botrule"><td styleCode="Lrule"> Grade 3/4</td><td styleCode="Lrule">7</td><td styleCode="Lrule Rrule">25</td></tr><tr><td styleCode="Lrule"><content styleCode="bold">Infection</content></td><td styleCode="Lrule"/><td styleCode="Lrule Rrule"/></tr><tr><td styleCode="Lrule"> Any</td><td styleCode="Lrule">35</td><td styleCode="Lrule Rrule">37</td></tr><tr styleCode="Botrule"><td styleCode="Lrule"> Grade 3/4</td><td styleCode="Lrule">8</td><td styleCode="Lrule Rrule">8</td></tr><tr><td styleCode="Lrule"><content styleCode="bold">Fever in absence of infection</content></td><td styleCode="Lrule"/><td styleCode="Lrule Rrule"/></tr><tr><td styleCode="Lrule"> Any</td><td styleCode="Lrule">33</td><td styleCode="Lrule Rrule">29</td></tr><tr styleCode="Botrule"><td styleCode="Lrule"> Grade 3/4</td><td styleCode="Lrule">&lt; 1</td><td styleCode="Lrule Rrule">1</td></tr><tr><td styleCode="Lrule"><content styleCode="bold">Hypersensitivity Reaction <footnote ID="K6776">Replaces NCI term &quot;Allergy&quot;</footnote></content></td><td styleCode="Lrule"/><td styleCode="Lrule Rrule"/></tr><tr><td styleCode="Lrule"> Any</td><td styleCode="Lrule">12</td><td styleCode="Lrule Rrule">4</td></tr><tr styleCode="Botrule"><td styleCode="Lrule"> Grade 3/4</td><td styleCode="Lrule">3</td><td styleCode="Lrule Rrule">&lt; 1</td></tr><tr><td styleCode="Lrule"><content styleCode="bold">Fluid Retention <footnote ID="F2">COSTART term and grading system</footnote></content></td><td styleCode="Lrule"/><td styleCode="Lrule Rrule"/></tr><tr><td styleCode="Lrule"> Any</td><td styleCode="Lrule">54</td><td styleCode="Lrule Rrule">42</td></tr><tr><td styleCode="Lrule"> All severe or life-threatening events</td><td styleCode="Lrule">2</td><td styleCode="Lrule Rrule">2</td></tr><tr><td styleCode="Lrule">Pleural effusion</td><td styleCode="Lrule"/><td styleCode="Lrule Rrule"/></tr><tr><td styleCode="Lrule"> Any</td><td styleCode="Lrule">23</td><td styleCode="Lrule Rrule">22</td></tr><tr><td styleCode="Lrule"> All severe or life-threatening events</td><td styleCode="Lrule">2</td><td styleCode="Lrule Rrule">2</td></tr><tr><td styleCode="Lrule">Peripheral edema</td><td styleCode="Lrule"/><td styleCode="Lrule Rrule"/></tr><tr><td styleCode="Lrule"> Any</td><td styleCode="Lrule">34</td><td styleCode="Lrule Rrule">18</td></tr><tr><td styleCode="Lrule"> All severe or life-threatening events</td><td styleCode="Lrule">&lt;1</td><td styleCode="Lrule Rrule">&lt;1</td></tr><tr><td styleCode="Lrule">Weight gain</td><td styleCode="Lrule"/><td styleCode="Lrule Rrule"/></tr><tr><td styleCode="Lrule"> Any</td><td styleCode="Lrule">15</td><td styleCode="Lrule Rrule">9</td></tr><tr styleCode="Botrule"><td styleCode="Lrule"> All severe or life-threatening events</td><td styleCode="Lrule">&lt;1</td><td styleCode="Lrule Rrule">&lt;1</td></tr><tr><td styleCode="Lrule"><content styleCode="bold">Neurosensory</content></td><td styleCode="Lrule"/><td styleCode="Lrule Rrule"/></tr><tr><td styleCode="Lrule"> Any</td><td styleCode="Lrule">47</td><td styleCode="Lrule Rrule">42</td></tr><tr styleCode="Botrule"><td styleCode="Lrule"> Grade 3/4</td><td styleCode="Lrule">4</td><td styleCode="Lrule Rrule">4</td></tr><tr><td styleCode="Lrule"><content styleCode="bold">Neuromotor</content></td><td styleCode="Lrule"/><td styleCode="Lrule Rrule"/></tr><tr><td styleCode="Lrule"> Any</td><td styleCode="Lrule">19</td><td styleCode="Lrule Rrule">17</td></tr><tr styleCode="Botrule"><td styleCode="Lrule"> Grade 3/4</td><td styleCode="Lrule">3</td><td styleCode="Lrule Rrule">6</td></tr><tr><td styleCode="Lrule"><content styleCode="bold">Skin</content></td><td styleCode="Lrule"/><td styleCode="Lrule Rrule"/></tr><tr><td styleCode="Lrule"> Any</td><td styleCode="Lrule">16</td><td styleCode="Lrule Rrule">14</td></tr><tr styleCode="Botrule"><td styleCode="Lrule"> Grade 3/4</td><td styleCode="Lrule">&lt;1</td><td styleCode="Lrule Rrule">1</td></tr><tr><td styleCode="Lrule"><content styleCode="bold">Nausea</content></td><td styleCode="Lrule"/><td styleCode="Lrule Rrule"/></tr><tr><td styleCode="Lrule"> Any</td><td styleCode="Lrule">72</td><td styleCode="Lrule Rrule">76</td></tr><tr styleCode="Botrule"><td styleCode="Lrule"> Grade 3/4</td><td styleCode="Lrule">10</td><td styleCode="Lrule Rrule">17</td></tr><tr><td styleCode="Lrule"><content styleCode="bold">Vomiting</content></td><td styleCode="Lrule"/><td styleCode="Lrule Rrule"/></tr><tr><td styleCode="Lrule"> Any</td><td styleCode="Lrule">55</td><td styleCode="Lrule Rrule">61</td></tr><tr styleCode="Botrule"><td styleCode="Lrule"> Grade 3/4</td><td styleCode="Lrule">8</td><td styleCode="Lrule Rrule">16</td></tr><tr><td styleCode="Lrule"><content styleCode="bold">Diarrhea</content></td><td styleCode="Lrule"/><td styleCode="Lrule Rrule"/></tr><tr><td styleCode="Lrule"> Any</td><td styleCode="Lrule">47</td><td styleCode="Lrule Rrule">25</td></tr><tr styleCode="Botrule"><td styleCode="Lrule"> Grade 3/4</td><td styleCode="Lrule">7</td><td styleCode="Lrule Rrule">3</td></tr><tr><td styleCode="Lrule"><content styleCode="bold">Anorexia <footnoteRef IDREF="F2"/></content></td><td styleCode="Lrule"/><td styleCode="Lrule Rrule"/></tr><tr><td styleCode="Lrule"> Any</td><td styleCode="Lrule">42</td><td styleCode="Lrule Rrule">40</td></tr><tr styleCode="Botrule"><td styleCode="Lrule"> All severe or life-threatening events</td><td styleCode="Lrule">5</td><td styleCode="Lrule Rrule">5</td></tr><tr><td styleCode="Lrule"><content styleCode="bold">Stomatitis</content></td><td styleCode="Lrule"/><td styleCode="Lrule Rrule"/></tr><tr><td styleCode="Lrule"> Any</td><td styleCode="Lrule">24</td><td styleCode="Lrule Rrule">21</td></tr><tr styleCode="Botrule"><td styleCode="Lrule"> Grade 3/4</td><td styleCode="Lrule">2</td><td styleCode="Lrule Rrule">1</td></tr><tr><td styleCode="Lrule"><content styleCode="bold">Alopecia</content></td><td styleCode="Lrule"/><td styleCode="Lrule Rrule"/></tr><tr><td styleCode="Lrule"> Any</td><td styleCode="Lrule">75</td><td styleCode="Lrule Rrule">42</td></tr><tr styleCode="Botrule"><td styleCode="Lrule"> Grade 3</td><td styleCode="Lrule">&lt;1</td><td styleCode="Lrule Rrule">0</td></tr><tr><td styleCode="Lrule"><content styleCode="bold">Asthenia <footnoteRef IDREF="F2"/></content></td><td styleCode="Lrule"/><td styleCode="Lrule Rrule"/></tr><tr><td styleCode="Lrule"> Any</td><td styleCode="Lrule">74</td><td styleCode="Lrule Rrule">75</td></tr><tr styleCode="Botrule"><td styleCode="Lrule"> All severe or life-threatening events</td><td styleCode="Lrule">12</td><td styleCode="Lrule Rrule">14</td></tr><tr><td styleCode="Lrule"><content styleCode="bold">Nail Disorder <footnoteRef IDREF="F2"/></content></td><td styleCode="Lrule"/><td styleCode="Lrule Rrule"/></tr><tr><td styleCode="Lrule"> Any</td><td styleCode="Lrule">14</td><td styleCode="Lrule Rrule">&lt;1</td></tr><tr styleCode="Botrule"><td styleCode="Lrule"> All severe events</td><td styleCode="Lrule">&lt;1</td><td styleCode="Lrule Rrule">0</td></tr><tr><td styleCode="Lrule"><content styleCode="bold">Myalgia <footnoteRef IDREF="F2"/></content></td><td styleCode="Lrule"/><td styleCode="Lrule Rrule"/></tr><tr><td styleCode="Lrule"> Any</td><td styleCode="Lrule">18</td><td styleCode="Lrule Rrule">12</td></tr><tr><td styleCode="Lrule"> All severe events</td><td styleCode="Lrule">&lt;1</td><td styleCode="Lrule Rrule">&lt;1</td></tr></tbody></table>

adverse reactions table

<table ID="table9" width="100%"><caption>Table 9: Clinically Important Treatment-Emergent Adverse Reactions (Regardless of Relationship) in Patients with Prostate Cancer Who Received Docetaxel in Combination with Prednisone (TAX327)</caption><col align="left" valign="top" width="40%"/><col align="center" valign="top" width="15%"/><col align="center" valign="top" width="15%"/><col align="center" valign="top" width="15%"/><col align="center" valign="top" width="15%"/><thead><tr styleCode="Botrule"><th styleCode="Lrule"/><th align="center" colspan="2" styleCode="Lrule Botrule">Docetaxel 75 mg/m <sup>2</sup>every 3 weeks + prednisone 5 mg twice daily n=332 % </th><th align="center" colspan="2" styleCode="Lrule Rrule Botrule">Mitoxantrone 12 mg/m <sup>2</sup>every 3 weeks + prednisone 5 mg twice daily n=335 % </th></tr><tr><th styleCode="Lrule">Adverse Reaction</th><th styleCode="Lrule">Any</th><th styleCode="Lrule">Grade 3/4</th><th styleCode="Lrule">Any</th><th styleCode="Lrule Rrule">Grade 3/4</th></tr></thead><tbody><tr styleCode="Botrule"><td styleCode="Lrule"><content styleCode="bold">Anemia</content></td><td styleCode="Lrule Botrule">67</td><td styleCode="Lrule Botrule">5</td><td styleCode="Lrule Botrule">58</td><td styleCode="Lrule Rrule Botrule">2</td></tr><tr styleCode="Botrule"><td styleCode="Lrule"><content styleCode="bold">Neutropenia</content></td><td styleCode="Lrule Botrule">41</td><td styleCode="Lrule Botrule">32</td><td styleCode="Lrule Botrule">48</td><td styleCode="Lrule Rrule Botrule">22</td></tr><tr styleCode="Botrule"><td styleCode="Lrule"><content styleCode="bold">Thrombocytopenia</content></td><td styleCode="Lrule Botrule">3</td><td styleCode="Lrule Botrule">1</td><td styleCode="Lrule Botrule">8</td><td styleCode="Lrule Rrule Botrule">1</td></tr><tr styleCode="Botrule"><td styleCode="Lrule"><content styleCode="bold">Febrile neutropenia</content></td><td styleCode="Lrule Botrule">3</td><td styleCode="Lrule Botrule">N/A</td><td styleCode="Lrule Botrule">2</td><td styleCode="Lrule Rrule Botrule">N/A</td></tr><tr styleCode="Botrule"><td styleCode="Lrule"><content styleCode="bold">Infection</content></td><td styleCode="Lrule Botrule">32</td><td styleCode="Lrule Botrule">6</td><td styleCode="Lrule Botrule">20</td><td styleCode="Lrule Rrule Botrule">4</td></tr><tr styleCode="Botrule"><td styleCode="Lrule"><content styleCode="bold">Epistaxis</content></td><td styleCode="Lrule Botrule">6</td><td styleCode="Lrule Botrule">0</td><td styleCode="Lrule Botrule">2</td><td styleCode="Lrule Rrule Botrule">0</td></tr><tr styleCode="Botrule"><td styleCode="Lrule"><content styleCode="bold">Allergic Reactions</content></td><td styleCode="Lrule Botrule">8</td><td styleCode="Lrule Botrule">1</td><td styleCode="Lrule Botrule">1</td><td styleCode="Lrule Rrule Botrule">0</td></tr><tr><td styleCode="Lrule"><content styleCode="bold">Fluid Retention <footnote ID="F1">Related to treatment</footnote></content></td><td styleCode="Lrule">24</td><td styleCode="Lrule">1</td><td styleCode="Lrule">5</td><td styleCode="Lrule Rrule">0</td></tr><tr><td styleCode="Lrule">Weight Gain <footnoteRef IDREF="F1"/></td><td styleCode="Lrule">8</td><td styleCode="Lrule">0</td><td styleCode="Lrule">3</td><td styleCode="Lrule Rrule">0</td></tr><tr styleCode="Botrule"><td styleCode="Lrule">Peripheral Edema <footnoteRef IDREF="F1"/></td><td styleCode="Lrule Botrule">18</td><td styleCode="Lrule Botrule">0</td><td styleCode="Lrule Botrule">2</td><td styleCode="Lrule Rrule Botrule">0</td></tr><tr styleCode="Botrule"><td styleCode="Lrule"><content styleCode="bold">Neuropathy Sensory</content></td><td styleCode="Lrule Botrule">30</td><td styleCode="Lrule Botrule">2</td><td styleCode="Lrule Botrule">7</td><td styleCode="Lrule Rrule Botrule">0</td></tr><tr styleCode="Botrule"><td styleCode="Lrule"><content styleCode="bold">Neuropathy Motor</content></td><td styleCode="Lrule Botrule">7</td><td styleCode="Lrule Botrule">2</td><td styleCode="Lrule Botrule">3</td><td styleCode="Lrule Rrule Botrule">1</td></tr><tr styleCode="Botrule"><td styleCode="Lrule"><content styleCode="bold">Rash/Desquamation</content></td><td styleCode="Lrule Botrule">6</td><td styleCode="Lrule Botrule">0</td><td styleCode="Lrule Botrule">3</td><td styleCode="Lrule Rrule Botrule">1</td></tr><tr styleCode="Botrule"><td styleCode="Lrule"><content styleCode="bold">Alopecia</content></td><td styleCode="Lrule Botrule">65</td><td styleCode="Lrule Botrule">N/A</td><td styleCode="Lrule Botrule">13</td><td styleCode="Lrule Rrule Botrule">N/A</td></tr><tr styleCode="Botrule"><td styleCode="Lrule"><content styleCode="bold">Nail Changes</content></td><td styleCode="Lrule Botrule">30</td><td styleCode="Lrule Botrule">0</td><td styleCode="Lrule Botrule">8</td><td styleCode="Lrule Rrule Botrule">0</td></tr><tr styleCode="Botrule"><td styleCode="Lrule"><content styleCode="bold">Nausea</content></td><td styleCode="Lrule Botrule">41</td><td styleCode="Lrule Botrule">3</td><td styleCode="Lrule Botrule">36</td><td styleCode="Lrule Rrule Botrule">2</td></tr><tr styleCode="Botrule"><td styleCode="Lrule"><content styleCode="bold">Diarrhea</content></td><td styleCode="Lrule Botrule">32</td><td styleCode="Lrule Botrule">2</td><td styleCode="Lrule Botrule">10</td><td styleCode="Lrule Rrule Botrule">1</td></tr><tr styleCode="Botrule"><td styleCode="Lrule"><content styleCode="bold">Stomatitis/Pharyngitis</content></td><td styleCode="Lrule Botrule">20</td><td styleCode="Lrule Botrule">1</td><td styleCode="Lrule Botrule">8</td><td styleCode="Lrule Rrule Botrule">0</td></tr><tr styleCode="Botrule"><td styleCode="Lrule"><content styleCode="bold">Taste Disturbance</content></td><td styleCode="Lrule Botrule">18</td><td styleCode="Lrule Botrule">0</td><td styleCode="Lrule Botrule">7</td><td styleCode="Lrule Rrule Botrule">0</td></tr><tr styleCode="Botrule"><td styleCode="Lrule"><content styleCode="bold">Vomiting</content></td><td styleCode="Lrule Botrule">17</td><td styleCode="Lrule Botrule">2</td><td styleCode="Lrule Botrule">14</td><td styleCode="Lrule Rrule Botrule">2</td></tr><tr styleCode="Botrule"><td styleCode="Lrule"><content styleCode="bold">Anorexia</content></td><td styleCode="Lrule Botrule">17</td><td styleCode="Lrule Botrule">1</td><td styleCode="Lrule Botrule">14</td><td styleCode="Lrule Rrule Botrule">0</td></tr><tr styleCode="Botrule"><td styleCode="Lrule"><content styleCode="bold">Cough</content></td><td styleCode="Lrule Botrule">12</td><td styleCode="Lrule Botrule">0</td><td styleCode="Lrule Botrule">8</td><td styleCode="Lrule Rrule Botrule">0</td></tr><tr styleCode="Botrule"><td styleCode="Lrule"><content styleCode="bold">Dyspnea</content></td><td styleCode="Lrule Botrule">15</td><td styleCode="Lrule Botrule">3</td><td styleCode="Lrule Botrule">9</td><td styleCode="Lrule Rrule Botrule">1</td></tr><tr styleCode="Botrule"><td styleCode="Lrule"><content styleCode="bold">Cardiac left ventricular function</content></td><td styleCode="Lrule Botrule" valign="middle">10</td><td styleCode="Lrule Botrule" valign="middle">0</td><td styleCode="Lrule Botrule" valign="middle">22</td><td styleCode="Lrule Rrule Botrule" valign="middle">1</td></tr><tr styleCode="Botrule"><td styleCode="Lrule"><content styleCode="bold">Fatigue</content></td><td styleCode="Lrule Botrule">53</td><td styleCode="Lrule Botrule">5</td><td styleCode="Lrule Botrule">35</td><td styleCode="Lrule Rrule Botrule">5</td></tr><tr styleCode="Botrule"><td styleCode="Lrule"><content styleCode="bold">Myalgia</content></td><td styleCode="Lrule Botrule">15</td><td styleCode="Lrule Botrule">0</td><td styleCode="Lrule Botrule">13</td><td styleCode="Lrule Rrule Botrule">1</td></tr><tr styleCode="Botrule"><td styleCode="Lrule"><content styleCode="bold">Tearing</content></td><td styleCode="Lrule Botrule">10</td><td styleCode="Lrule Botrule">1</td><td styleCode="Lrule Botrule">2</td><td styleCode="Lrule Rrule Botrule">0</td></tr><tr><td styleCode="Lrule"><content styleCode="bold">Arthralgia</content></td><td styleCode="Lrule">8</td><td styleCode="Lrule">1</td><td styleCode="Lrule">5</td><td styleCode="Lrule Rrule">1</td></tr></tbody></table>

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.